4:10 PM
 | 
Nov 08, 2018
 |  BioCentury  |  Finance

Biomatics’ next phase

How Biomatics’ growing team will support its second fund’s strategy

Biomatics Capital plans to take a more active role in company formation and seek more neuroscience investments with its second fund, and has brought on two partners to implement its strategy.

With Fund II, which closed at $300 million on Thursday, Biomatics’ Julie Sunderland said, “we’ve gotten more nuanced and will focus on three specific areas,” including therapeutics and diagnostics, enabling R&D technologies and data-driven clinical practice tools. The VC closed its...

Read the full 338 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >